Q1 FY2027 EarningsQ1 FY27 beat consensus across top and bottom-line metrics, with revenue of $1.48M significantly exceeding the $0.17M expectation due to a $1.2M one-time recognition from a licensing agreement. GAAP Net Loss of $13.0M was narrower than the anticipated $15.1M, and Diluted EPS of -$0.30 beat the consensus of -$0.36. While fasedienol missed its primary endpoint in the PALISADE-4 trial, positive post-hoc data in severe populations and a $31.7M cash position provide a bridge to late-2026/early-2027 operations.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Vistagen Therap(VTGN) the Revenue is 1.476 M (+504.9%), Beat estimate;the EBIT is -13.35 M (+15.54%), Beat estimate;the EPS is -0.3 (+36.17%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B504.92%
0.00B31.69%
+0.00B536.61%
EBITExceed expectations
-0.01B15.54%
-0.02B2.13%
+0.00B13.41%
EPSExceed expectations
-0.336.17%
-0.36522.34%
+0.065013.83%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf